+ Public Healthcare

What we know about AIDS

What we know about AIDS explains the essential science of HIV succinctly and clearly. It was originally published as a chapter in Debunking Delusions by Nathan Geffen. With the permission of the author, Nathan Geffen, and the book’s publisher, Jacana, aidstruth.org has released this chapter under the Creative Commons Share-Alike 3.0 Unported license.

Report on investigation into infant deaths at Charlotte Maxeke Hospital released

SECTION27 welcomes the release of the report on the investigation into the tragic deaths of six infants on 18 May 2010 at the Charlotte Maxeke Academic Hospital (“the Hospital”) in Johannesburg. The report raises serious concerns about the extent to which the Gauteng Department of Health and Social Development (“the Department”) adheres to norms and standards related to human resources, and the consequent overcrowding in public health facilities in the province.

The Global Health Workforce Alliance launches new website

The Global Health Workforce Alliance announces the launch of a microsite, developed in partnership with the Guardian, to highlight and raise awarenes of the global health workforce crisis ahead of the Second Global Forum on Human Resources for Health, in Bangkok, 25 – 29 January 2011.

University of Johannesburg and MSF Discussion Report – Dialogue 2

Médecins Sans Frontières/Doctors without Borders (MSF) and the University of Johannesburg’s (UJ’s) Faculty of Health Sciences have partnered to raise awareness and encourage discussion on public health-related issues through a series of high-level debates. In the second of this series, the panel addressed critical issues from challenges hampering the ability of the public health system to provide treatment, care and support, to legal frameworks and opportunities such as innovative financing mechanisms for global health.

Study proves that a pill a day reduces the risk of HIV infection amongst men who have sex with men

SECTION27 and the Treatment Action Campaign (TAC) welcome the results of the Pre-exposure Prophylaxis Initiative (iPrEX) trial. Published yesterday in the New England Journal of Medicine (NEJM), the study is the first to establish that pre-exposure prophylaxis (PrEP) – taking antiretroviral (ARV) medicines before sex – reduces the risk of HIV infection. It follows closely on the heels of the CAPRISA 004 trial, which demonstrated that the use of tenofovir 1% gel reduced the risk of HIV infection amongst women at increased risk.

The iPrEx trial enrolled 2499 men who have sex with men (MSM) at 11 sites across the world (including Cape Town). Half of the trial participants were randomly assigned to take a daily dose of two ARV medicines – tenofovir disproxil fumarate (TDF) and emtricitabine (FTC) – combined into a single pill. The other half, also randomly assigned, received a daily placebo. All received a comprehensive package of HIV prevention services, including regular HIV testing, risk-reduction counselling, condoms, and the treatment of symptomatic sexually transmitted infections.